Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
<levothyroxine sodium, mechanism, androgens>, <levothyroxine sodium, mechanism, anabolic hormones>, <levothyroxine sodium, mechanism, asparaginase>, <levothyroxine sodium, mechanism, clofibrate>, <levothyroxine sodium, mechanism, estrogens>, <levothyroxine sodium, mechanism, estrogen-containing compounds>, <levothyroxine sodium, mechanism, 5-fluorouracil>, <levothyroxine sodium, mechanism, furosemide>, <levothyroxine sodium, mechanism, glucocorticoids>, <levothyroxine sodium, mechanism, meclofenamic acid>, <levothyroxine sodium, mechanism, mefenamic acid>, <levothyroxine sodium, mechanism, methadone>, <levothyroxine sodium, mechanism, perphenazine>, <levothyroxine sodium, mechanism, phenylbutazone>, <levothyroxine sodium, mechanism, phenytoin>, <levothyroxine sodium, mechanism, salicylates>, <levothyroxine sodium, mechanism, tamoxifen>